Risk of hepatocellular carcinoma after hepatitis C virus cure

Table 2 Current therapies for treatment of chronic hepatitis C

Year approved	FDA approved therapy	Genotype	Trade name
2011	PegIFN/RBV + Boceprevir	Genotype-1	Victrelis®
2011	Telaprevir + PegIFNα/RBV	Genotype-1	Incivek®
2013	Sofosbuvir + RBV or Sofosbuvir + PegIFNα/RBV	Genotype-1, 2, 3 and 4	Sovaldi®
2014	Ledipasvir + Sofosbuvirwith or without RBV	Genotype-1, 4, 5 and 6	Harvoni®
2015	Daclatasvir + Sofosbuvir with or without RBV	Genotype-1, and 3	Daklinza™ + Sovaldi®
2016	Grazoprevir + Elbasvir + RBV	Genotype-1, and 4	Zepatier™
2016	Velpatasvir + Sofosbuvir	Genotype 1 to 6	Epclusa®
2017	Glecaprevir + Pibrentasvir	Genotype 1 to 6	Mavyret™
2017	Sofosbuvir + Velpatasvir + Voxilaprevir	Genotype 1 to 6	Vosevi®

FDA: Food and Drug Administration; RBV: Ribavirin; IFN: Interferon.